News
GSK ends decades-long hiatus in oral antibiotics for UTIs
The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.
R&D
Sponsored
Exploring the future: Opportunities and challenges in cell a...
Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.
R&D
Deep Dive: Research and Development 2025
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
R&D
Life Sciences Industry Report - Part 7
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Oncology
Life Sciences Industry Report - Part 5
Developments in the oncology space in 2024 brought hope to both industry and patients.
R&D
Partner Content
Return to Europe for the 2nd IMPACCT Real World Evidence Sum...
The IMPACCT Real World Evidence Summit is back, offering the opportunity to bring together 50+ pharma RWE decision makers to discuss integrated evidence plans, data sharing optimization, infrastruc
R&D
Partner Content
4th Circular & Self-Amplifying RNA Therapeutics Summit
With CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine, the field of next generation RNAs celebrates the potential of circular and self-am
Category :
Views & Analysis
/
